General Partner Inc’s AstraZeneca AZN Stock Holding History

General Partner Inc’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.8K	Hold	384	–	–	0.04%	124
2026 Q1	$75.7K	Hold	384	–	–	0.05%	117
2025 Q4	$70.6K	Hold	384	–	–	0.04%	118
2025 Q3	$58.9K	Hold	384	–	–	0.03%	127
2025 Q2	$53.7K	Hold	384	–	–	0.03%	128
2025 Q1	$56.4K	Hold	384	–	–	0.04%	122
2024 Q4	$50.3K	Hold	384	–	–	0.03%	126
2024 Q3	$59.8K	Hold	384	–	–	0.04%	118
2024 Q2	$59.9K	Hold	384	–	–	0.04%	114
2024 Q1	$52K	Buy	+384	New	+$50.8K	0.03%	127

Other funds holding AZN

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ZIC

ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

CAM

Cidel Asset Management Toronto, Ontario, Ontario, Canada $2.08B AUM 24.89% 1-Year Est. Return

SAM

Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return

PAS

Professional Advisory Services Vero Beach, Florida $836M AUM 25.79% 1-Year Est. Return

MIM

Martin Investment Management Palm Beach Gardens, Florida $300M AUM 6.05% 1-Year Est. Return

NONA

Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

General Partner Inc's AZN Position: Q2 2026 in Review

General Partner Inc held its AstraZeneca (AZN) position steady in Q2 2026 at 384 shares worth $72.8K. The position accounts for 0.04% of the portfolio, ranked #124.

General Partner Inc first reported a position in AZN in Q1 2024 and has held it in 10 quarters since. The position peaked at $75.7K in Q1 2026. 233 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

General Partner Inc held 384 shares of AstraZeneca worth $72.8K as of Q2 2026.
General Partner Inc left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.04% of General Partner Inc's portfolio in Q2 2026, its #124 holding.
General Partner Inc first reported a position in AstraZeneca in Q1 2024 and has held it in 10 quarters since.
General Partner Inc's AstraZeneca position peaked at $75.7K in Q1 2026.
233 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on General Partner Inc's 13F filing for Q2 2026, filed 6 Jul 2026.